FXR activators reduce lipid levels in the liver by inhibiting the expression of lipogenic genes and reducing lipid absorption in patients and mouse models of non-alcoholic fatty liver disease (Clifford et al., 2021). The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.